These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 36702145)

  • 1. Is tezepelumab the ubiquitous biologic for severe asthma?
    Beasley R; Chang AB
    Lancet Respir Med; 2023 May; 11(5):393-395. PubMed ID: 36702145
    [No Abstract]   [Full Text] [Related]  

  • 2. The potential promise and challenge for tezepelumab as a biologic therapy for severe asthma.
    Williams DM
    J Manag Care Spec Pharm; 2022 May; 28(5):581-583. PubMed ID: 35471066
    [No Abstract]   [Full Text] [Related]  

  • 3. When to stop biologicals. Severe asthma exacerbation after mepolizumab discontinuation.
    Bagnasco D; Aloè T; Sclifò F; Ferrantino MG; Marugo F; Arcadipane F; Manfredi A; Canonica GW; Passalacqua G
    Eur Ann Allergy Clin Immunol; 2019 May; 51(3):135-137. PubMed ID: 31081606
    [No Abstract]   [Full Text] [Related]  

  • 4. Biologics for paediatric severe asthma: trick or TREAT?
    Saglani S; Bush A; Carroll W; Cunningham S; Fleming L; Gaillard E; Gupta A; Murray C; Nagakumar P; Paton J; Roberts G; Seddon P; Sinha I
    Lancet Respir Med; 2019 Apr; 7(4):294-296. PubMed ID: 30824361
    [No Abstract]   [Full Text] [Related]  

  • 5. Tezepelumab (Tezspire) for severe asthma.
    Med Lett Drugs Ther; 2022 Feb; 64(1644):25-26. PubMed ID: 35171894
    [No Abstract]   [Full Text] [Related]  

  • 6. Severe Eosinophilic Allergic Asthma Responsive to Mepolizumab After Failure of 2 Consecutive Biologics.
    Sánchez-Jareño M; Barranco P; Romero D; Domínguez-Ortega J; Quirce S
    J Investig Allergol Clin Immunol; 2019 Feb; 29(1):79-81. PubMed ID: 30785114
    [No Abstract]   [Full Text] [Related]  

  • 7. Pediatric asthma: guidelines-based care, omalizumab, and other potential biologic agents.
    Huffaker MF; Phipatanakul W
    Immunol Allergy Clin North Am; 2015 Feb; 35(1):129-44. PubMed ID: 25459581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biologics for severe asthma.
    Faulconer M; Sheridan D
    Nursing; 2024 Apr; 54(4):13-15. PubMed ID: 38517494
    [No Abstract]   [Full Text] [Related]  

  • 9. Severe asthma: When to resort to biological agents.
    Tenero L; Rossignoli S; Piacentini G
    Pediatr Allergy Immunol; 2020 Feb; 31 Suppl 24():37-39. PubMed ID: 32017206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In severe, uncontrolled asthma, tezepelumab reduced exacerbations and improved asthma control at 1 y.
    Taleb AA; Badgett RG
    Ann Intern Med; 2021 Oct; 174(10):JC115. PubMed ID: 34606305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic and Pharmacodynamic Modeling of Tezepelumab to Guide Phase 3 Dose Selection for Patients With Severe Asthma.
    Ly N; Zheng Y; Griffiths JM; van der Merwe R; Agoram B; Parnes JR; Roskos L
    J Clin Pharmacol; 2021 Jul; 61(7):901-912. PubMed ID: 33368307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of Biologics in Asthma.
    McGregor MC; Krings JG; Nair P; Castro M
    Am J Respir Crit Care Med; 2019 Feb; 199(4):433-445. PubMed ID: 30525902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The potential of biologics for the treatment of asthma.
    Pelaia G; Vatrella A; Maselli R
    Nat Rev Drug Discov; 2012 Dec; 11(12):958-72. PubMed ID: 23197041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biologics for asthma and comorbid nasal polyps.
    Weinberger MM; Hendeles L
    Ann Allergy Asthma Immunol; 2024 Oct; 133(4):356-357. PubMed ID: 39293898
    [No Abstract]   [Full Text] [Related]  

  • 15. Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma.
    Menzies-Gow A; Corren J; Bourdin A; Chupp G; Israel E; Wechsler ME; Brightling CE; Griffiths JM; Hellqvist Å; Bowen K; Kaur P; Almqvist G; Ponnarambil S; Colice G
    N Engl J Med; 2021 May; 384(19):1800-1809. PubMed ID: 33979488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tezepelumab compared with other biologics for the treatment of severe asthma: a systematic review and indirect treatment comparison.
    Menzies-Gow A; Steenkamp J; Singh S; Erhardt W; Rowell J; Rane P; Martin N; Ackert JL; Quinton A
    J Med Econ; 2022; 25(1):679-690. PubMed ID: 35570578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of tezepelumab in patients with uncontrolled disease while receiving maintenance therapy for moderate or severe asthma.
    Corren J; Wechsler ME; Chupp G; Roseti SL; Hellqvist Å; Martin N; Llanos JP; Ambrose CS; Colice G
    J Allergy Clin Immunol Pract; 2023 Mar; 11(3):943-945.e2. PubMed ID: 36375743
    [No Abstract]   [Full Text] [Related]  

  • 18. Disconnect for Tezepelumab on Exacerbations, Symptoms, and Quality of Life in Type 2 Low Asthma.
    Lipworth B; Chan R
    Am J Respir Crit Care Med; 2023 Jul; 208(2):211. PubMed ID: 37279364
    [No Abstract]   [Full Text] [Related]  

  • 19. Switching between biologics in severe asthma patients. When the first choice is not proven to be the best.
    Papaioannou AI; Fouka E; Papakosta D; Papiris S; Loukides S
    Clin Exp Allergy; 2021 Feb; 51(2):221-227. PubMed ID: 33305478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dramatic Response to Tezepelumab as an Initial Biologic Agent for Refractory Asthma Associated with Type 2 and Non-type 2 Traits.
    Minami D; Hosoya T; Hosoya M; Nagano A; Nakajima Y; Miyahara N; Kanehiro A
    Acta Med Okayama; 2023 Dec; 77(6):671-674. PubMed ID: 38145943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.